BioCentury | Dec 12, 2020
Product Development

Ipsen is casting a wider BD net under new CEO Loew

...year, represents Ipsen’s best near-term growth prospect. However, partner Exelixis Inc....
BioCentury | Dec 10, 2020
Deals

More enthusiasm for ADCs as Boehringer buys NBE, gaining conjugate platform

...the target of which is undisclosed; as well as programs partnered with Sotio a.s. and Exelixis Inc....
BioCentury | Dec 3, 2020
Finance

Dec. 2 Quick Takes: venture rounds for Genesis, Biosight; plus: Frontier-AbbVie, Exelixis-Iconic, UCB-Specifica and Click

...and is eligible for more than $1 billion in milestones, plus royalties. Exelixis in-licenses ADC from Iconic Exelixis Inc....
...cognitive and neurobehavioral disorders. TARGETSTF (CD142; thromboplastin) – Tissue factor BC Staff Genesis Therapeutics Inc. AbbVie Inc. Frontier Medicines Corp. Biosight Ltd. Exelixis Inc. Iconic...
BioCentury | Sep 23, 2020
Product Development

Immunomedics data point to Trodelvy’s $21B potential

...Clinical Oncology (ASCO) meeting in May (see “ASCO Data Bring New Markets Within Reach”). BMS and Exelixis Inc....
...Other) Cometriq (Brand), Cabometyx (Brand), XL184 (Compound #), cabozantinib (Generic), Cometriq (Other), Cabometyx (Other) Amgen Inc. Bristol-Myers Squibb Co. Exelixis Inc. Immunomedics...
BioCentury | Sep 9, 2020
Product Development

Sept. 8 Quick Takes: Phase III wins for Albireo, Merck and Spero; plus Corbus, Blueprint, AnHeart, Grifols-Alkahest, and Exelixis-NBE

...Alkahest for $37.5 million in cash (see “Age Factors”).Exelixis...
...AG received $25 million up front from Exelixis Inc....
...conjugate (ADC) platform, which uses anthracycline-based payloads. Exelixis...
BioCentury | Apr 20, 2020
Product Development

Opdivo-Cabometyx combo improves PFS by 49%, OS by 40% in first-line RCC

...a 40% risk reduction on the OS endpoint (HR=0.60; p<0.001). Ipsen Group (Euronext:IPN; Pink:IPSEY) and Exelixis Inc....
...for instance with the European Society of Medical Oncology (ESMO) clinical guideline update in February. Exelixis...
...sales of the drug exceeded $1 billion over a four-quarter period ended Sept. 30, 2019; Exelixis...
BioCentury | Mar 4, 2020
Management Tracks

Karp, Ghosh depart Biogen; plus Exelixis, Senti, Applied Therapeutics, Oncopeptides, Acacia and more

...CEO due to personal reasons while remaining chairman. Biogen did not disclose Karp’s next appointment. Exelixis Inc....
...Inc. twoXAR Inc. Rafael Pharmaceuticals Inc. Addex Therapeutics Ltd. Celyad S.A. Sumitomo Dainippon Pharma Co. Ltd. Acacia Pharma Group plc Oncopeptides AB Biogen Inc. Exelixis Inc. Unity...
BioCentury | Feb 14, 2020
Finance

You say you want a Revolution? Oncology company is latest to post big gain after IPO

...trial as a monotherapy and a Phase Ib/II study in combination with Cotellic cobimetinib from Exelixis Inc....
BioCentury | Feb 11, 2020
Product Development

Exelixis eyeing 2021 combo submission in prostate cancer following new readout

...Provenge sipuleucel-T, according to National Comprehensive Cancer Network treatment guidelines (see “Prostate Cancer Disrupted” ). Exelixis Inc....
...cohort that began with 30 patients, but grew to 80 following a July 2019 expansion. Exelixis...
...results from the study have driven Exelixis’ decisions to start pivotal trials in those indications. Exelixis...
BioCentury | Nov 22, 2019
Clinical News

Tecentriq-Avastin combo poised to become SOC for hepatocellular carcinoma

...Tecentriq Approval ” and “ Tecentriq First Front-Line SCLC Therapy in Decades ”). Roche and Exelixis Inc....
Items per page:
1 - 10 of 965
BioCentury | Dec 12, 2020
Product Development

Ipsen is casting a wider BD net under new CEO Loew

...year, represents Ipsen’s best near-term growth prospect. However, partner Exelixis Inc....
BioCentury | Dec 10, 2020
Deals

More enthusiasm for ADCs as Boehringer buys NBE, gaining conjugate platform

...the target of which is undisclosed; as well as programs partnered with Sotio a.s. and Exelixis Inc....
BioCentury | Dec 3, 2020
Finance

Dec. 2 Quick Takes: venture rounds for Genesis, Biosight; plus: Frontier-AbbVie, Exelixis-Iconic, UCB-Specifica and Click

...and is eligible for more than $1 billion in milestones, plus royalties. Exelixis in-licenses ADC from Iconic Exelixis Inc....
...cognitive and neurobehavioral disorders. TARGETSTF (CD142; thromboplastin) – Tissue factor BC Staff Genesis Therapeutics Inc. AbbVie Inc. Frontier Medicines Corp. Biosight Ltd. Exelixis Inc. Iconic...
BioCentury | Sep 23, 2020
Product Development

Immunomedics data point to Trodelvy’s $21B potential

...Clinical Oncology (ASCO) meeting in May (see “ASCO Data Bring New Markets Within Reach”). BMS and Exelixis Inc....
...Other) Cometriq (Brand), Cabometyx (Brand), XL184 (Compound #), cabozantinib (Generic), Cometriq (Other), Cabometyx (Other) Amgen Inc. Bristol-Myers Squibb Co. Exelixis Inc. Immunomedics...
BioCentury | Sep 9, 2020
Product Development

Sept. 8 Quick Takes: Phase III wins for Albireo, Merck and Spero; plus Corbus, Blueprint, AnHeart, Grifols-Alkahest, and Exelixis-NBE

...Alkahest for $37.5 million in cash (see “Age Factors”).Exelixis...
...AG received $25 million up front from Exelixis Inc....
...conjugate (ADC) platform, which uses anthracycline-based payloads. Exelixis...
BioCentury | Apr 20, 2020
Product Development

Opdivo-Cabometyx combo improves PFS by 49%, OS by 40% in first-line RCC

...a 40% risk reduction on the OS endpoint (HR=0.60; p<0.001). Ipsen Group (Euronext:IPN; Pink:IPSEY) and Exelixis Inc....
...for instance with the European Society of Medical Oncology (ESMO) clinical guideline update in February. Exelixis...
...sales of the drug exceeded $1 billion over a four-quarter period ended Sept. 30, 2019; Exelixis...
BioCentury | Mar 4, 2020
Management Tracks

Karp, Ghosh depart Biogen; plus Exelixis, Senti, Applied Therapeutics, Oncopeptides, Acacia and more

...CEO due to personal reasons while remaining chairman. Biogen did not disclose Karp’s next appointment. Exelixis Inc....
...Inc. twoXAR Inc. Rafael Pharmaceuticals Inc. Addex Therapeutics Ltd. Celyad S.A. Sumitomo Dainippon Pharma Co. Ltd. Acacia Pharma Group plc Oncopeptides AB Biogen Inc. Exelixis Inc. Unity...
BioCentury | Feb 14, 2020
Finance

You say you want a Revolution? Oncology company is latest to post big gain after IPO

...trial as a monotherapy and a Phase Ib/II study in combination with Cotellic cobimetinib from Exelixis Inc....
BioCentury | Feb 11, 2020
Product Development

Exelixis eyeing 2021 combo submission in prostate cancer following new readout

...Provenge sipuleucel-T, according to National Comprehensive Cancer Network treatment guidelines (see “Prostate Cancer Disrupted” ). Exelixis Inc....
...cohort that began with 30 patients, but grew to 80 following a July 2019 expansion. Exelixis...
...results from the study have driven Exelixis’ decisions to start pivotal trials in those indications. Exelixis...
BioCentury | Nov 22, 2019
Clinical News

Tecentriq-Avastin combo poised to become SOC for hepatocellular carcinoma

...Tecentriq Approval ” and “ Tecentriq First Front-Line SCLC Therapy in Decades ”). Roche and Exelixis Inc....
Items per page:
1 - 10 of 965